Pfizer Inc (PFE)

PFE on New York Consolidated

29.13USD
11 Feb 2016
Change (% chg)

$-0.36 (-1.22%)
Prev Close
$29.49
Open
$29.01
Day's High
$29.34
Day's Low
$28.89
Volume
39,640,150
Avg. Vol
37,024,560
52-wk High
$36.46
52-wk Low
$28.25

PFE

Chart for PFE

About

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX,... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $182,041.80
Shares Outstanding(Mil.): 6,173.00
Dividend: 0.30
Yield (%): 4.07

Financials

  PFE Industry Sector
P/E (TTM): 23.83 31.28 37.85
EPS (TTM): 1.24 -- --
ROI: -- 14.74 14.09
ROE: -- 15.31 14.83
Search Stocks

Pfizer unveils management line up for combined company

Pfizer Inc , which agreed to buy Allergan Plc for $160 billion last year, unveiled its management line up for the combined company, once the deal closes in the second half of 2016.

08 Feb 2016

UPDATE 1-Pfizer unveils management line up for combined company

Feb 8 Pfizer Inc, which agreed to buy Allergan Plc for $160 billion last year, unveiled its management line up for the combined company, once the deal closes in the second half of 2016.

08 Feb 2016

Pfizer to create operating unit after Allergan deal closes

Feb 8 Pfizer Inc, which agreed to buy Allergan Plc for $160 billion last year, said it will create a new operating unit to house its consumer healthcare and Allergan's opthalmology and Botox units once the deal closes in the second half of 2016.

08 Feb 2016

FDA reviewers support Celltrion's biosimilar Remicade

Feb 5 U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency.

05 Feb 2016

AstraZeneca warns on profits in 2016 as Crestor patent loss weighs

LONDON AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling cholesterol drug, which will offset growth in sales of newer medicines.

04 Feb 2016

UPDATE 3-AstraZeneca warns on profits in 2016 as Crestor patent loss weighs

* Q4 revenue $6.40 billion vs consensus $6.29 billion (Adds details on management incentives, further reaction)

04 Feb 2016

AstraZeneca says new lung cancer pill Tagrisso approved by EU

LONDON, Feb 3 AstraZeneca said its new lung cancer pill Tagrisso won early approval for use in the EU, three months after U.S. authorities gave it the green light, in a boost for the company.

03 Feb 2016

Pfizer 2016 forecast disappoints

U.S. drugmaker Pfizer Inc on Tuesday forecast 2016 revenue and earnings below analysts' estimates, largely because of the strong dollar.

02 Feb 2016

UPDATE 4-Pfizer 2016 forecast disappoints

Feb 2 U.S. drugmaker Pfizer Inc on Tuesday forecast 2016 revenue and earnings below analysts' estimates, largely because of the strong dollar.

02 Feb 2016

Pfizer revenue rises as pneumonia vaccine sales jump

Feb 2 Pfizer Inc, which has agreed to buy Botox-maker Allergan Plc for $160 billion, reported a 7 percent rise in quarterly revenue, helped by its Hospira acquisition and demand for its pneumonia vaccine.

02 Feb 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks